Advertisement

Abdominal Imaging

, Volume 36, Issue 6, pp 671–676 | Cite as

Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization)

  • Ralf Thorsten Hoffmann
  • P. Paprottka
  • T. F. Jakobs
  • C. G. Trumm
  • M. F. Reiser
Article

Abstract

Treatment of primary and secondary hepatic malignancies with transarterial chemoembolization (TACE) represents an essential component of interventional oncology known for many years and performed by many interventional radiologists first in primary liver tumors and nowadays even in metastases of different origins. Radioembolization (RE) has been introduced to the clinical arsenal of cytoreductive modalities in recent years. There is growing evidence for efficiency in liver tumors of various entities, with the most prominent ones being hepatocellular carcinoma, colorectal cancer, and neuroendocrine tumors. Hepatic metastases of other tumor entities (breast cancer, malignant melanoma, and pancreatic cancer) are treatment-sensitive. This article focuses on procedural and technical aspects for selection, preparation, and performance of treatment as well as the results in metastatic breast cancer, neuroendocrine tumors, melanoma, and pancreatic cancer giving an overview of the results after RE, transarterial embolization, or TACE.

Keywords

Transarterial chemoembolization Radioembolization Selective internal radiotherapy Neuroendocrine tumors Breast cancer Malignant melanoma Pancreatic cancer 

References

  1. 1.
    Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251–1278PubMedCrossRefGoogle Scholar
  2. 2.
    Abdalla EK, et al. (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239(6):818–825 (discussion 825–827)PubMedCrossRefGoogle Scholar
  3. 3.
    Mulcahy MF, et al. (2009) Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115(9):1849–1858PubMedCrossRefGoogle Scholar
  4. 4.
    Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30(5):969–977PubMedGoogle Scholar
  5. 5.
    Lammer J, et al. (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52PubMedCrossRefGoogle Scholar
  6. 6.
    Raoul JL, et al. (1992) Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70(3):585–590PubMedCrossRefGoogle Scholar
  7. 7.
    Gonsalves CF, Brown DB (2009) Chemoembolization of hepatic malignancy. Abdom Imaging 34:557–565PubMedCrossRefGoogle Scholar
  8. 8.
    Chen MS, et al. (2002) High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 8(1):74–78PubMedGoogle Scholar
  9. 9.
    Higashi S, et al. (1999) Size of lipid microdroplets effects results of hepatic arterial chemotherapy with an anticancer agent in water-in-oil-in-water emulsion to hepatocellular carcinoma. J Pharmacol Exp Ther 289(2):816–819PubMedGoogle Scholar
  10. 10.
    Touzios JG, et al. (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241(5):776–783 (discussion 783–785)PubMedCrossRefGoogle Scholar
  11. 11.
    Yip D, et al. (2004) Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. J Gastroenterol Hepatol 19(3):347–349PubMedCrossRefGoogle Scholar
  12. 12.
    Lau WY, et al. (1998) Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40(3):583–592PubMedCrossRefGoogle Scholar
  13. 13.
    Ibrahim SM, Nikolaidis P, Miller FG, et al. (2009) Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 34:566–581PubMedCrossRefGoogle Scholar
  14. 14.
    Riaz A, et al. (2009) Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 20(9):1121–1130 (quiz 1131)PubMedCrossRefGoogle Scholar
  15. 15.
    Viadana E, Bross ID, Pickren JW (1973) An autopsy study of some routes of dissemination of cancer of the breast. Br J Cancer 27(4):336–340PubMedCrossRefGoogle Scholar
  16. 16.
    Giroux MF, Baum RA, Soulen MC (2004) Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol 15(3):289–291PubMedGoogle Scholar
  17. 17.
    Jakobs TF, et al. (2008) Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 19(5):683–690PubMedCrossRefGoogle Scholar
  18. 18.
    Bangash AK, et al. (2007) 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 18(5):621–628PubMedCrossRefGoogle Scholar
  19. 19.
    Coldwell DM, Kennedy AS, Nutting CW (2007) Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 69(3):800–804PubMedCrossRefGoogle Scholar
  20. 20.
    Murthy R, et al. (2008) Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 19(1):145–151PubMedCrossRefGoogle Scholar
  21. 21.
    Madoff DC, et al. (2006) Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 17(8):1235–1249 (quiz 1250)PubMedCrossRefGoogle Scholar
  22. 22.
    Gonsalves CF, Brown DB (2009) Chemoembolization of hepatic malignancy. Abdom Imaging 34(5):557–565PubMedCrossRefGoogle Scholar
  23. 23.
    Gupta S, et al. (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8):1590–1602PubMedCrossRefGoogle Scholar
  24. 24.
    Rhee TK, et al. (2008) 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 247(6):1029–1035PubMedCrossRefGoogle Scholar
  25. 25.
    Kennedy AS, et al. (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31(3):271–279PubMedCrossRefGoogle Scholar
  26. 26.
    Ahmadzadehfar H, Biersack HJ, Ezziddin S (2010) Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 40(2):105–121PubMedCrossRefGoogle Scholar
  27. 27.
    Kalinowski M, et al. (2009) Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 79(3):137–142PubMedCrossRefGoogle Scholar
  28. 28.
    Mavligit GM, et al. (1988) Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 260(7):974–976PubMedCrossRefGoogle Scholar
  29. 29.
    Bedikian AY, et al. (1995) Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76(9):1665–1670PubMedCrossRefGoogle Scholar
  30. 30.
    Sharma KV, et al. (2008) Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol 190(1):99–104PubMedCrossRefGoogle Scholar
  31. 31.
    Schuster R, et al. (2010) Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 20(3):191–196PubMedGoogle Scholar
  32. 32.
    Kennedy AS, et al. (2009) A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 27(6):682–690PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ralf Thorsten Hoffmann
    • 1
  • P. Paprottka
    • 2
  • T. F. Jakobs
    • 2
  • C. G. Trumm
    • 2
  • M. F. Reiser
    • 2
  1. 1.Institute and Clinic for RadiologyUniversity Hospital of DresdenDresdenGermany
  2. 2.Institute of Clinical RadiologyUniversity of MunichMunichGermany

Personalised recommendations